SQLE, the second rate-limiting enzyme in the cholesterol biosynthesis, was found to be elevated in several cancers such as hepatocellular carcinoma, breast cancer, head and neck squamous cell carcinoma, and prostate cancer, contributing to tumor progression and poorer outcomes for patients [17–20]. This evidence concerns the gene SQLE and Familial prostate cancer.